Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003621 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma

A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target
18
Study locations

NCT00003621 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 29 participants, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (84% lower). The trial reports 18 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003621, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target
18
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have newly diagnosed anaplastic astrocytoma.

Conditions Studied

Brain and Central Nervous System Tumors

Interventions

  • DRUG cisplatin
  • DRUG etoposide
  • RADIATION radiation therapy
  • DRUG carmustine

Study Locations (18)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • CentraCare Clinic - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

North Dakota

  • Quain & Ramstad Clinic, P.C. - Bismarck
  • Altru Health Systems - Grand Forks

South Dakota

  • Rapid City Regional Hospital - Rapid City
  • CCOP - Sioux Community Cancer Consortium - Sioux Falls

Arizona

  • CCOP - Scottsdale Oncology Program - Scottsdale

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria

Kansas

  • CCOP - Wichita - Wichita

Louisiana

  • CCOP - Ochsner - New Orleans

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 1999-02
Est. Completion 2005-07
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00003621

The ClinicalTrials.gov registry entry for NCT00003621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (84% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.

NCT00003621 reports 18 study locations spanning 11 distinct geographic areas - top geographies include Minnesota, Iowa, North Dakota.

Frequently Asked Questions

What is clinical trial NCT00003621 about?

NCT00003621 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study th...

What is the current status of trial NCT00003621?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 1999-02. Estimated completion is 2005-07.

What conditions does trial NCT00003621 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.

What interventions are being tested in trial NCT00003621?

The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), radiation therapy (RADIATION), carmustine (DRUG).

Who is sponsoring clinical trial NCT00003621?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003621 being conducted?

This trial has 18 study locations across Arizona, Illinois, Iowa, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Brain and Central Nervous System Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Brain and Central Nervous System Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.